-
Je něco špatně v tomto záznamu ?
Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer
F. Soria, A. Giordano, SF. Shariat, P. Gontero,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
- MeSH
- aplikace intravezikální MeSH
- BCG vakcína terapeutické užití MeSH
- genetická terapie * MeSH
- imunoterapie * MeSH
- invazivní růst nádoru MeSH
- léčba šetřící orgány metody MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- nádory močového měchýře terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
PURPOSE OF REVIEW: The treatment of bacillus Calmette-Guérin (BCG) unresponsive disease remains a challenge for urooncologists. The search for effective conservative treatments is ongoing and several new agents have been recently tested for this purpose. The aim of this manuscript was to review the last developments in this interesting field. RECENT FINDINGS: The advent of systemic immunotherapy in the nonmuscle invasive setting promise to revolutionize the paradigm of treatment of BCG unresponsive disease. The preliminary results of the Keynote-057 trial (3 months complete response of 41% in carcinoma-in-situ patients) have led to the rapid approval of pembrolizumab from the Food and Drug Administration. Interesting results have been reported for gene therapies such as those with CG0700 and Adstiladrin, nonreplicating adenovirus able to increase the 'in situ' antitumor activity. However, larger prospective trials with longer follow-up are needed to confirm the initial findings. SUMMARY: In summary, early radical cystectomy remains the standard treatment for BCG unresponsive patients. However, in case of patients unfit for or refusing radical cystectomy, the bladder-sparing options are continuously increasing. Although BCG-reinduction (with or without interferon) and traditional intravesical chemotherapy may represent the past, the present and the future are characterized by device-assisted therapies, systemic immunotherapy, and gene therapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028042
- 003
- CZ-PrNML
- 005
- 20210114152847.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MOU.0000000000000789 $2 doi
- 035 __
- $a (PubMed)32427633
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Soria, Francesco $u Department of Surgical Sciences, Division of Urology, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
- 245 10
- $a Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer / $c F. Soria, A. Giordano, SF. Shariat, P. Gontero,
- 520 9_
- $a PURPOSE OF REVIEW: The treatment of bacillus Calmette-Guérin (BCG) unresponsive disease remains a challenge for urooncologists. The search for effective conservative treatments is ongoing and several new agents have been recently tested for this purpose. The aim of this manuscript was to review the last developments in this interesting field. RECENT FINDINGS: The advent of systemic immunotherapy in the nonmuscle invasive setting promise to revolutionize the paradigm of treatment of BCG unresponsive disease. The preliminary results of the Keynote-057 trial (3 months complete response of 41% in carcinoma-in-situ patients) have led to the rapid approval of pembrolizumab from the Food and Drug Administration. Interesting results have been reported for gene therapies such as those with CG0700 and Adstiladrin, nonreplicating adenovirus able to increase the 'in situ' antitumor activity. However, larger prospective trials with longer follow-up are needed to confirm the initial findings. SUMMARY: In summary, early radical cystectomy remains the standard treatment for BCG unresponsive patients. However, in case of patients unfit for or refusing radical cystectomy, the bladder-sparing options are continuously increasing. Although BCG-reinduction (with or without interferon) and traditional intravesical chemotherapy may represent the past, the present and the future are characterized by device-assisted therapies, systemic immunotherapy, and gene therapy.
- 650 _2
- $a aplikace intravezikální $7 D000283
- 650 _2
- $a BCG vakcína $x terapeutické užití $7 D001500
- 650 12
- $a genetická terapie $7 D015316
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a imunoterapie $7 D007167
- 650 _2
- $a invazivní růst nádoru $7 D009361
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a léčba šetřící orgány $x metody $7 D059351
- 650 _2
- $a nádory močového měchýře $x terapie $7 D001749
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Giordano, Andrea $u Department of Surgical Sciences, Division of Urology, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Department of Urology, Weill Cornell Medical College, New York, New York, USA.
- 700 1_
- $a Gontero, Paolo $u Department of Surgical Sciences, Division of Urology, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
- 773 0_
- $w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 30, č. 4 (2020), s. 542-546
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32427633 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152845 $b ABA008
- 999 __
- $a ok $b bmc $g 1608377 $s 1119222
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 30 $c 4 $d 542-546 $e - $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
- LZP __
- $a Pubmed-20210105